The INSIGHT Community Advisory Board have released a statement in response to a change in the US treatment guidelines in December 2009 that stated that antiretroviral treatment should be universally started at any CD4 count below 500 cells/mm3.
The START study is currently enrolling patients to look at whether there is evidence to support such a recommendation. Currently no randomised trial has provided data on the advantages and risks of earlier treatment. This statement affirms both the importance of the START trial and the safety for people who enrol.
Download the CAB Statement on START (pdf, 101kb)
For more information please contact: email@example.com